All In Biotech

Drug Trial Radar · NCT06328777

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Systemic Sclerosis

Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

37

Planned (sponsor's estimate)

Start

Jul 2, 2024

Primary completion

Jul 2029

Study completion Jul 2029

Sponsor

Lead sponsor
Cabaletta BioIndustry
Sponsor type
Industry
First posted
Mar 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RESET-SSc: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T cell therapy, in Subjects with Systemic Sclerosis

Conditions

  • Systemic Sclerosis
  • Scleroderma
  • Interstitial Lung Diseases

Interventions

  • CABA-201Biological

    Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide

  • CABA-201Biological

    Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1/2: To evaluate incidence of adverse eventsTime frame: Up to 28 days after CABA-201 infusion
  2. Phase 2b Sub-study: To evaluate the efficacy of CABA-201 on % predicted forced vital capacity (FVC) in SSc-ILD subjectsTime frame: Week 52

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Yale University

    New Haven, Connecticut · Recruiting

  • Mayo Clinic Florida

    Jacksonville, Florida · Recruiting

  • Northwestern Memorial Hospital

    Chicago, Illinois · Recruiting

  • The University of Chicago Medical Center

    Chicago, Illinois · Recruiting

  • University of Kansas Medical Center

    Kansas City, Kansas · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Mayo Clinic Rochester

    Rochester, Minnesota · Recruiting

  • Columbia University Irving Medical Center

    New York, New York · Recruiting

  • University of Rochester

    Rochester, New York · Recruiting

  • Duke University

    Durham, North Carolina · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.